This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Moody's Places Amgen Debt on Review

Last week's Food and Drug Administration advisory panel on Amgen's (AMGN - Get Report) Aranesp for chemotherapy-induced anemia led one debt rating agency to rethink the drugmaker's debt rating.

Moody's placed the Thousand Oaks, Calif.- based company's A2 long-term and Prime-1 short term ratings -- approximately $11.2 billion of rated debt -- under review for possible downgrade on Monday.

Last week an FDA advisory panel recommended that anemia drugs such as Aranesp and Johnson & Johnson's (JNJ - Get Report) Procrit be further limited in their use in cancer patients, based on evidence of negative side effects.

The panel determined the drugs should not be used in patients with metastatic breast cancer or cancer of the head and neck, and voted to bar the use of anemia drugs in cancer patients with "curative" disease. The panel did vote against entirely restricting the use of anemia drugs in cancer, and also voted down a suggestion that the drug only be used in patients with small cell lung cancer.

The ruling has the potential to weigh most heavily on Amgen, which counts on Aranesp as its top-selling drug.

"Although the panel recommendation does not represent a worst-case scenario, Moody's has previously stated that Amgen's key credit ratios may not have sufficient cushion to absorb any further decline in Aranesp sales at the current rating level," according to a Moody's press release.

Moody's said concern about Amgen's late-stage pipeline, emerging competitive pressures, and Amgen's history of share repurchases and acquisitions that have stressed its credit ratios also played into the decision for a rating review.

It will consider the anticipated decline in Aranesp sales, potential of cost saving initiatives, opportunities for revenue growth (such as osteoperosis candidate denosumab) and the company's financial policies.

Moody's revised its ratings outlook for Amgen to negative from stable in May of last year.

Amgen's shares closed down 3.1% at 43.08 on Monday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $158.30 -1.41%
JNJ $112.08 -0.36%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs